Evidence map›Paper›PMID 21408124›Full record

ArticlePLoS neglected tropical diseases2011

Co-administration of a plasmid DNA encoding IL-15 improves long-term protection of a genetic vaccine against Trypanosoma cruzi.

Christopher S Eickhoff, Jose R Vasconcelos, Nicole L Sullivan, Azra Blazevic, Oscar Bruna-Romero, Mauricio M Rodrigues, Daniel F Hoft

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Use ofFrontiers in microbiology · 2022
    Article
  7. Why do we still have not a vaccine against Chagas disease?Memorias do Instituto Oswaldo Cruz · 2022
    Review
  8. Article
  9. Article
  10. Article
  11. Genetic Engineering ofFrontiers in microbiology · 2018
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Christopher S EickhoffDepartment of Internal Medicine, Saint Louis University, Saint Louis, Missouri, USA.
Jose R Vasconcelos
Nicole L Sullivan
Azra Blazevic
Oscar Bruna-Romero
Mauricio M Rodrigues
Daniel F Hoft
Saint Louis University · USUniversidade Federal de Minas Gerais · BRUniversidade Federal de São Paulo · BR

Funding

TRYPANOSOMA CRUZI MUCOSAL &SYSTEMIC PROTECTIVE IMMUNITYR01AI040196 · NIAID · SAINT LOUIS UNIVERSITY · PI HOFT, DANIEL F. · 1999 to 2008
$2.7M
NIAID NIH HHS R01 AI040196
6 · The paper itself

Abstract

backgroundImmunization of mice with the Trypanosoma cruzi trans-sialidase (TS) gene using plasmid DNA, adenoviral vector, and CpG-adjuvanted protein delivery has proven highly immunogenic and provides protection against acute lethal challenge. However, long-term protection induced by TS DNA vaccines has not been reported. The goal of the present work was to test whether the co-administration of a plasmid encoding IL-15 (pIL-15) could improve the duration of protection achieved through genetic vaccination with plasmid encoding TS (pTS) alone. METHODOLOGY: We immunized BALB/c mice with pTS in the presence or absence of pIL-15 and studied immune responses [with TS-specific IFN-γ ELISPOT, serum IgG ELISAs, intracellular cytokine staining (IFN-γ, TNF-α, and IL-2), tetramer staining, and CFSE dilution assays] and protection against lethal systemic challenge at 1 to 6 months post vaccination. Mice receiving pTS alone developed robust TS-specific IFN-γ responses and survived a lethal challenge given within the first 3 months following immunization. The addition of pIL-15 to pTS vaccination did not significantly alter T cell responses or protection during this early post-vaccination period. However, mice vaccinated with both pTS and pIL-15 challenged 6 months post-vaccination were significantly more protected against lethal T. cruzi challenges than mice vaccinated with pTS alone (P<0.05). Improved protection correlated with significantly higher numbers of TS-specific IFN-γ producing total and CD8(+) T cells detected>6 months post immunization. Also, these TS-specific T cells were better able to expand after in vitro re-stimulation.

conclusionAddition of pIL-15 during genetic vaccination greatly improved long-term T cell survival, memory T cell expansion, and long-term protection against the important human parasite, T. cruzi.

Indexed as

Adjuvants, ImmunologicAnimalsAntibodies, ProtozoanChagas DiseaseCytokinesEnzyme-Linked Immunosorbent AssayEnzyme-Linked Immunospot AssayFemaleGlycoproteinsInterleukin-15MiceMice, Inbred BALB CNeuraminidaseOligodeoxyribonucleotidesPlasmidsProtozoan VaccinesAdjuvants, ImmunologicAntibodies, ProtozoanCPG-oligonucleotideCytokinesGlycoproteinsInterleukin-15NeuraminidaseOligodeoxyribonucleotidesProtozoan Vaccinestrans-sialidaseVaccines, DNAVaccines, Synthetic

Identifiers

PMID21408124
PMCPMC3050911
OpenAlexW1981491341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.